KRAS and adenoma: This kit examines two DNA methylation markers (NDRG4 and BMP3), seven KRAS mutation markers, one beta actin normalization marker, and one conventional fecal hemoglobin marker to get a high sensitivity of 92.3% for CRC and 42.4% for advanced adenoma, with a specificity of 86.6% in 9,989 asymptomatic individuals [7].